Next Phase Newsletter

The firm is a family office spin-off established in 2023 with offices in New York and Toronto, Canada. The firm invests globally through two complementary arms. The early-stage arm focuses on Pre-Seed and Seed opportunities in North America, typically writing first checks between USD $500k–2.5M into deeptech companies. The later-stage arm is dedicated exclusively to life sciences investments, with flexibility on check sizes and a global focus. While the firm does not typically lead rounds, it participates actively on a case-by-case basis. 

The early-stage strategy emphasizes deeptech companies—such as biotech, AI, space-tech, and medtech—while generally avoiding pure life sciences unless there is a strong technology angle, such as medical devices. The later-stage strategy targets Phase I–III ready drug assets. The firm is disease-agnostic, including orphan indications, but prefers companies addressing at least 5% of the population. Across both strategies, the firm favors companies pursuing FDA approval in the U.S. 

The firm does not have strict company or management team requirements, but appreciates teams with academic backgrounds or ties to universities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a venture capital group based in New Jersey with a dedicated life sciences fund that invests primarily at the Seed stage. The fund typically commits around USD $1 million per company and is flexible in taking either a lead or co-investor role. Its geographic focus spans North America and Europe. 

Within life sciences, the fund targets therapeutics, medical technology, digital health, and biotech ecosystem companies that address age-related diseases such as cardiovascular disease, cancer, respiratory illnesses, dementia, Alzheimer’s, diabetes, and kidney disease. 

On the therapeutics side, the fund emphasizes “repair and replace” technologies, including regenerative medicine, gene therapy, and immunotherapy. In medtech, it is particularly interested in wearables, biosensors, and remote patient monitoring solutions. For digital health, the focus extends to AI-driven drug discovery and clinical trial optimization. Within the broader biotech ecosystem, areas of interest include bioprinting, biomaterials, and novel drug delivery systems. 

The firm seeks companies built on strong scientific foundations, offering innovative and scalable solutions. It values management teams with diverse expertise across science, business development, administration, and marketing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A global pharmaceutical company headquartered in Europe with offices worldwide is specialized in rare diseases, respiratory conditions, and critical care. The firm actively seeks partnerships with early-stage companies and is open to a variety of collaboration structures, including co-development, SAFE agreements, in-licensing, and acquisitions, depending on the opportunity. 

Its Center for Open Innovation focuses on early-stage, pre-clinical assets, technologies, and digital or device-based healthcare solutions beyond the concept stage. Meanwhile, the business development and external innovation team engages with later-stage companies. With a strong international presence, the firm actively pursues opportunities across North America, Europe, and Asia. 

The firm concentrates on rare diseases, respiratory health, and critical care. While its main focus is on therapeutics, it also considers diagnostics, medical devices, and digital health opportunities. The Center for Open Innovation targets assets in the target identification and optimization phases (TRL 3–5/6), prioritizing technologies that are novel and transformative rather than incremental. 

Although the firm maintains defined therapeutic priorities, it remains open to adjacent or complementary innovation areas outside its existing pipeline. 

The firm values partners that emphasize environmental sustainability and social responsibility. Ideal management teams bring complementary expertise and a clear commitment to delivering  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A professional investment institution was founded in 2016 and headquartered in Shanghai, China. Through its fund management entity, the group invests in early- and growth-stage companies within the biomedicine sector. The firm currently manages a fund of approximately RMB ¥100 million, making equity investments typically ranging from ¥5 million to ¥20 million in Angel through Series B rounds. It is actively seeking opportunities in China, the United States, and Canada. 

The firm focuses on medicine, medical devices, diagnostics, biotechnology, and healthcare services. It seeks products with strong market potential in China that have already achieved prototype development and clinical proof-of-concept. The firm maintains an indication-agnostic approach, evaluating opportunities based on innovation and scalability rather than specific therapeutic areas. 

The firm looks for capable management teams leading companies with validated assets. It can support portfolio companies by facilitating registration and distribution partnerships in China and may request regional rights depending on the structure of the collaboration. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 The firm is an early-stage life sciences focused venture capital investor. The firm targets Series A investment rounds but considers later stage investments and plans to make follow-on commitments throughout a company’s life cycle. Typical initial check sizes can range from $1M to $2.5M. The firm may lead or co-invest on a case-by-case basis and often syndicates with other strong life science investors. The firm invests across the United States, with a focus on underserved or underrepresented regions. 
 
The firm is interested in medical devices, diagnostics, digital health, and medical instruments. The firm does not invest in traditional drug assets but may consider peripheral areas such as drug delivery or platform technologies. For medical devices, the firm primarily considers products with B2B models and a clear FDA regulatory pathway. The firm is opportunistic in terms of indications/disease areas. For development stage, the firm prefers companies with products or assets that are within 18 months of commercialization and have a well-defined regulatory pathway. 
 

There is no specific requirement for companies and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 An impact venture investor focuses on healthcare and climate, with specialized teams for each vertical. With its current fund, the firm is allocating €1M for initial checks with flexibility to make follow-on investments. The firm invests in Seed rounds but can enter earlier or later. The firm’s investments are focused in Europe.  
 

In healthcare, the firm is technology agnostic and invests in solutions that help improve the quality of life for vulnerable populations: the elderly, people with chronic diseases, and people with mental or physical disabilities. For digital health companies, the firm seeks to see product-market fit. 

The firm can act as a lead investor and join syndicates. The firm requests to take a board seat, as it prefers to be an active investor. The firm would like to see committed and diverse management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A life sciences-focused venture capital investor based in the US is actively seeking new investment opportunities. In addition, the firm recently closed on a new fund through its specialized funds business unit that invests in companies in Asia. The firm generally supports companies with lead assets that can reach high-value inflection points in 3–4 years and will consider opportunities in the U.S., Canada, Europe, Singapore, Hong Kong, and China. 

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. It is therapeutic area agnostic, though it has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers later-stage opportunities, particularly those that have received market approval with early revenue. 

The firm does not have any specific requirements for management teams. It is an active investor and seeks a director or observer position on portfolio company boards. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology